Kopran Ltd
Kopran Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY 2024-25 Revenue from Operations: Rs. Q4 FY 2024-25 Financials (Page 5): - EBITDA: Rs.
From Kopran Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
- Q4 FY 2023-24 Revenue from Operations: Rs. 18,608 Lakhs
- Year-on-Year Change in Quarterly Revenue: Decrease of Rs. 1,372 Lakhs (~7.37% decline)
- Q4 FY 2024-25 Formulations Revenue: Rs. 7,227 Lakhs (no direct YoY figure provided for Q4 formulations revenue)
- Q4 FY 2024-25 APIs Revenue: Rs. 9,710 Lakhs (no direct YoY figure provided for Q4 APIs revenue)
- FY 2024-25 Total Sales/Other Income: Rs. 63,359 Lakhs
- FY 2023-24 Total Sales/Other Income: Rs. 62,920 Lakhs
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
- Setting up of an API and R&D facility at Panoli is mentioned as part of growth strategy (Page 15).
- No specific amounts, timelines, or detailed project statuses are provided in the presentation regarding capex or new plant construction.
- Emphasis on capacity expansion is aligned with developing high-value/high-volume APIs and intermediates (Page 15).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Kopran Ltd Q4 FY25 results?
Q4 FY 2024-25 Revenue from Operations: Rs. Q4 FY 2024-25 Financials (Page 5): - EBITDA: Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.